RxDoctor Payments Data

Alicia Encinas, NP

Family · Cerritos, CANPI 1548859895

Payments from drug & device makers

$4,779in general payments, 2019–2025

Across 253 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$660
  • Takeda Pharmaceuticals U.S.A., Inc.$565
  • Aimmune Therapeutics, Inc.$408
  • Ipsen Biopharmaceuticals, Inc$224
  • Madrigal Pharmaceuticals$183
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,779 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$55,752
Medicare patients
471
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase62$339,505
ClenpiqSod Picosulf/Mag Ox/Citric Ac359$62,513
CreonLipase/Protease/Amylase19$60,062
LinzessLinaclotide44$57,866
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates132$7,885
Dexlansoprazole DrDexlansoprazole20$6,215
Omeprazole212$4,374
Sucralfate62$4,082
Famotidine226$4,035
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C25$3,664
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag26$3,308
Pantoprazole Sodium168$1,951
Esomeprazole Magnesium16$1,020
Cholestyramine LightCholestyramine17$827
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl46$678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$408$339,50562 claims
AbbVieCreon, Linzess$1,287$117,92863 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$112$3,66425 claims
Braintree Laboratories, Inc.Suflave$51$3,30826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Cerritos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →